Not all patients with CLL call for therapy. Regardless of all new advances, the iwCLL continue to suggests watchful observation for patients with asymptomatic condition.86 This advice relies on no less than two randomized trials comparing observation to possibly chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).助成事